Personalized rosuvastatin therapy in problem patients with partial statin intolerance

Area of Science:

• Pharmacogenetics
• Cardiovascular Disease
• Drug Metabolism

Background:

• Coronary artery disease (CAD) patients often experience statin intolerance.
• Ethnic Uzbek population presents unique challenges in statin therapy management.

Purpose of the Study:

• Investigate pharmacogenetic factors influencing the switch from simvastatin to rosuvastatin in intolerant Uzbek patients with CAD.
• Identify genetic markers associated with successful rosuvastatin treatment in this cohort.

Main Methods:

• Case-control study of 50 CAD patients with simvastatin intolerance and 50 controls.
• Genotyping for CYP3A5, CYP2C9, SLCO1B1, and ABCG2 polymorphisms using PCR-RFLP.
• Analysis of adverse event rates upon switching to rosuvastatin.

Main Results:

• 58% of simvastatin-intolerant patients tolerated the switch to rosuvastatin.
• A significant association was found between the CYP3A5 *3/*3 genotype and successful rosuvastatin treatment (OR=5.25, p=0.014).
• The CYP3A5 *3/*3 genotype was present in 72.4% of patients who tolerated rosuvastatin.

Conclusions:

• Switching to rosuvastatin is feasible for a significant portion of ethnic Uzbek CAD patients with simvastatin intolerance.
• The CYP3A5 *3/*3 genotype is a key pharmacogenetic determinant for successful rosuvastatin therapy in this population.
• Genetic profiling can guide personalized statin therapy selection to improve patient outcomes.